- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
IND Filed for Gene Therapy to Treat Scleroderma
Fibrocell Science has submitted an Investigational New Drug Application (IND) with the FDA for a gene therapy candidate to treat moderate to severe localized scleroderma.
Fibrocell Science has submitted an Investigational New Drug Application (IND) with the FDA for a gene therapy candidate to treat moderate to severe localized scleroderma.
Localized scleroderma, a chronic, immune-mediated skin disorder that affects approximately 90,000 US patients, typically begins between the ages of 20 to 50. The disease manifests as excess collagen production that results in fibrosis of the skin and connective tissue. Moderate to severe forms of scleroderma can result in significant morbidity.
Fibrocell’s proposed therapy, FCX-013, is an autologous fibroblast that has been genetically modified and encoded for matrix metalloproteinase 1 (MMP-1), a protein that is responsible for breaking down collagen. FCX-013 is designed for subcutaneous injection at the location of the fibrotic lesions, where the genetically modified fibroblast cells will produce MMP-1 to break down accumulated collagen. At the same time, the patient will take an oral compound that will help facilitate MMP-1 expression. Once the fibrosis has resolved, the patient will cease taking the oral compound.
If eventually approved, FCX-013 will provide a new therapeutic option for patients with scleroderma. Currently available treatments are symptomatic and supportive in nature; systemic or topical corticosteroids may be used, and light therapy or physical therapy may be employed. Medications that help to control fibrosis include D-penicillamine and cholchicine, and angiotensin-converting enzyme inhibitors may be used to treat kidney disease associated with scleroderma. The localized administration of FCX-013 could help patients avoid the adverse effects that are associated with systemic therapy.
Fibrocell is also working on gene therapies to target other disease that affect the skin and connective tissue. The most advanced product candidate in the company’s pipeline is FCX-007, which is in phase 1 and 2 clinical development for the treatment of recessive dystrophic epidermolysis bullosa, a disorder characterized by widespread blistering of the skin that may lead to scarring. The company is also in the research phase for potential gene therapies to target arthritis and related conditions.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
